Agios Pharma (AGIO) Stock Statistics & Valuation Metrics

Agios Pharma has a market cap or net worth of $2.36B. The enterprise value is $1.43B.

Agios Pharma has 58,313,812 shares outstanding. The number of shares has decreased by -2.65% in one year.

Agios Pharma’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is -24.99%.

The current PE Ratio of Agios Pharma is ―. Agios Pharma’s PEG ratio is -0.00964.

In the last 12 months, Agios Pharma had revenue of 36.50M and earned 673.73M in profits. Earnings per share was 11.86.

In the last 12 months, operating cash flow was -409.93M and capital expenditures -4.16M, giving a free cash flow of -414.09M billion.

Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Agios Pharma upcoming earnings date is Feb 12, 2026, TBA (Confirmed).

Agios Pharma as a current ratio of 11.90, with Debt / Equity ratio of 3.47%

In the past 12 months, Agios Pharma has paid 44.24M in taxes.

Agios Pharma EV to EBITDA ratio is -4.40, with an EV/FCF ratio of -4.72.

Agios Pharma has $952.86M in cash and marketable securities with $44.52M in debt, giving a net cash position of $908.35M billion.

Gross margin is 84.41%, with operating margin of -1166.47%, and net profit margin of 1845.92%.

The average price target for Agios Pharma is $49.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy